Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

ities to monetize the company's extensive fragment- based drug discovery capabilities, its preclinical programs and/or its intellectual property portfolio through a potential spin out or strategic alliance.

Sunesis will continue to benefit from any down-stream milestones or royalties based on future progress made in compounds emerging from its existing drug discovery collaborations with Biogen Idec Inc., Johnson & Johnson Pharmaceutical Research and Development LLC, Merck & Co., Inc. and SARcode Corporation. Sunesis anticipates that one or more of these compounds may advance to clinical trials within the next twelve months.

With this restructuring, Sunesis is reducing its workforce by approximately 60 employees. In addition, executive team members Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer, William L. Schary, Ph.D., Vice President, Regulatory Affairs and Quality Assurance, Robert S. McDowell, Ph.D., Vice President, Research and Jennifer A. Troia, SPHR, Vice President, Human Resources and Corporate Operations, will be leaving the company. Employees affected by the restructuring will be eligible for a severance package that includes severance pay, continuation of benefits and professional outplacement services. A one-time charge of approximately $10.7 million is expected to be incurred in the second quarter of 2008. Approximately $8.0 million of this charge is related to the closing of the company's research facility. Approximately $2.5 million of the restructuring charge represents cash payments over the next twelve months for severance and other personnel related expenses.

"The decision to undertake this workforce reduction is a difficult one. I deeply appreciate all of the past contributions made on behalf of Sunesis by the talented and committed employees affected by this realignment. I am confident that the ongoing team will build upon their legacy as we aggressively advance voreloxin through late-st
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LOS ANGELES , May 24, 2013  An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... , GLENVIEW, Ill. , Feb. 11 ... to announce the recipients of this year,s Presidential Commendations and Awards ... Gallagher , MD, MPH . This year,s recipients were recognized at ... week, where more than 800 scientists and physicians convened to learn ...
... , , NEW YORK , Feb. 11 ... telecommunication firms are strategically poised to capitalize on rapid ... are increasingly looking for innovative ways to collaborate with ... patients. Despite near universal agreement among pharmaceutical industry executives ...
Cached Medicine Technology:The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 2The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 3The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 4Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 2Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 3Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 4Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 5
(Date:5/25/2013)... 25, 2013 Pradaxa lawsuits ... episodes of internal bleeding while using the blood thinner continue ... Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... side effect claims had been filed in the ... 705 claims reported by the Court on May 15th. ( ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May ... brain cancer research and advocacy, comments on a new ... that shows incorporating cold atmospheric plasma into brain cancer ... , According to a Science Daily article, ... (MPE), biologists and physicians demonstrated the “synergistic effect of ...
(Date:5/25/2013)... Dr. Farooq Ashraf, founder of the Atlanta Vision ... his practice’s adoption of The iFS Advanced Femtosecond Laser. ... proven with more than 10 years of clinical research ... “We are happy to announce that we will now ... LASIK practice,” Ashraf said Thursday. “We have been using ...
(Date:5/25/2013)... The Slim Weight Patch has been clinically proven many ... to the highly sought after ingredients that have been used ... extra 2 months supply & premium membership of Slimming+ to ... you desire faster than ever. , Click Here to ... weight patch consumers can observe instant results within only a ...
(Date:5/25/2013)... For college students, few events ... they are turning to prescription stimulants like Adderall ... more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . ... that students who pick up Adderall, “just to ... developing a physical and psychological dependency. While initially ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... 12 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today that it will report fourth-quarter ... for 2009 on Monday, January 26, before the market ... investors to discuss the results beginning at 8:30 a.m. ...
... Lilly and Company,(NYSE: LLY ) today filed ... (SEC) detailing the pro forma impact of the company,s ... available on the,SEC,s website at www.sec.gov and ... www.investor.lilly.com . , The content ...
... VANCOUVER, Jan. 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ... million for the quarter and $141.9 million for the full ... quarter declined by 32.7% over the same quarter in 2007 ... annual sales in 2007. Sales in the U.S. for the ...
... Ranir, LLC, a leading,consumer products oral care company, ... foremost manufacturer and marketer of interdental oral,care products ... San Diego,California, Placontrol is the founder of the ... disclosed. , Ranir, headquartered ...
... Genomma Lab Internacional,S.A.B. de C.V. (BMV: LAB) ("Genomma ... the Company signed an agreement with IXE Casa de ... for the Company,s outstanding shares, thus,becoming another company to ... valid upon approval of the Mexican Stock Exchange (Bolsa,Mexicana ...
... has negative impact- No similar material exposures are expected ... wins are strong; service revenue expected to increase by ... Corporation (Nasdaq: PRXL ) has received notification ... unable to continue to make payments that are due ...
Cached Medicine News:Health News:Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results 2Health News:QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008 2Health News:Ranir, LLC Announces the Acquisition of Placontrol, Inc. 2Health News:Genomma Lab, New Participant in Market-Maker Program 2Health News:PAREXEL Reports Preliminary Second Quarter Results 2Health News:PAREXEL Reports Preliminary Second Quarter Results 3Health News:PAREXEL Reports Preliminary Second Quarter Results 4Health News:PAREXEL Reports Preliminary Second Quarter Results 5Health News:PAREXEL Reports Preliminary Second Quarter Results 6
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
Medicine Products: